EGFR is not amplified in ameloblastoma

• Autor(a) principal: Costa, Victor [UNESP]
• Data de Publicação: 2018
• Outros Autores: Fregnani, Eduardo Rodrigues, Fonseca, Felipe Paiva, Abreu Alves, Fábio, Pinto, Clóvis Antônio Lopes, Kaminagakura, Estela [UNESP]
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNESP
• Texto Completo: http://dx.doi.org/10.1016/j.oooo.2018.02.014; http://hdl.handle.net/11449/170820

Objective: The aim of this study was to investigate alterations in the EGFR gene and its protein expression for a better understanding of the biologic behavior of ameloblastoma. Study Design: Twenty-five samples of ameloblastoma were selected, and dual-color fluorescence in situ hybridization assay was performed. The results of the assay and immunohistochemistry reaction for EGFR and Ki67 were associated with clinicopathologic features and recurrence. Results: All analyzed cases presented disomy without any gene polysomy or amplification. With regard to EGFR immunoexpression, 3 cases (12%) were considered negative, and 22 (88%) were positive, of which 13 (52%) were weak and 9 (36%) were strong. All samples presented low positivity for Ki67. There was no association between EGFR expression and clinicopathologic features or recurrence (P >.05). In some cases, EGFR immunoexpression was observed without gene amplification. Conclusions: Ameloblastoma development, progression, or recurrence does not appear to be related to EGFR amplification or polysomy.